Physician profile
Gabriela A Maloney
NPI 1225411481
$724,927.76
in general payments reported to CMS, 2019-2025
34 companies · $307K in 2025
The $307K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $253 · 2021: $817 · 2022: $2,823 · 2023: $171K · 2024: $243K · 2025: $307K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $526K · Travel and Lodging: $102K · Consulting Fee: $73K · Food and Beverage: $19K · Education: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $526,049.00 |
| Travel and Lodging | $102,355.33 |
| Consulting Fee | $72,971.48 |
| Food and Beverage | $19,004.06 |
| Education | $425.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $231,728.22 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $140,889.51 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $124,534.83 | 2021-2025 | Otezla, Otezla |
| Abbvie INC. | $74,172.05 | 2019-2025 | |
| Lilly USA, LLC | $61,788.94 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $47,886.97 | 2019-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $27,393.40 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| E.R. Squibb & Sons, L.L.C. | $7,964.98 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $3,551.22 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,865.00 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $974.22 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $339.94 | 2019-2025 | |
| Pfizer INC. | $256.51 | 2020-2025 | |
| Incyte Corporation | $207.13 | 2022-2025 | Opzelura |
| Allergan, INC. | $199.73 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $164.65 | 2022-2024 | Tremfya |
| Organon LLC | $127.55 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $115.26 | 2019-2025 | |
| Sandoz INC. | $107.78 | 2023-2025 | Hyrimoz |
| Arcutis Biotherapeutics, INC. | $93.76 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $89.95 | 2023 | |
| Dermavant Sciences, INC. | $74.34 | 2022-2023 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $66.84 | 2022-2023 | Valchlor |
| Springworks Therapeutics, INC. | $57.62 | 2025 | Gomekli |
| Journey Medical Corporation | $47.16 | 2022-2025 | |
| Botanix Sb INC | $44.90 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.04 | 2023-2024 | Spevigo |
| Genentech USA, INC. | $33.82 | 2022-2025 | Xolair |
| Biocon Biologics INC | $24.03 | 2025 | Yesintek |
| Verrica Pharmaceuticals INC. | $23.53 | 2023 | Ycanth |
| Mallinckrodt Hospital Products INC. | $18.14 | 2025 | Acthar |
| Lnhc, INC | $18.06 | 2025 | Zelsuvmi |
| Prugen, INC. Pharmaceuticals | $15.82 | 2019 | |
| Dusa Pharmaceuticals, INC. | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriela Maloney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.